Drugs / Talaporfin
Talaporfin
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01924273 | Jun 2013 → Jul 2017 | — | University of California, Irvine | Completed | No outcome recorded |
| Phase 1 | NCT00709488 | Jun 2008 → Apr 2011 | benign prostatic hyperplasia | Light Sciences Oncology | Completed | No outcome recorded |
| Phase 1 | NCT00102115 | Dec 2004 → Jan 2006 | choroidal neovascularization, macular degeneration | Light Sciences LLC | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00122876 | Apr 2005 → Oct 2006 | hepatocellular carcinoma | Light Sciences Oncology | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00918034 | May 2009 → Feb 2011 | benign prostatic hyperplasia | Light Sciences Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00083785 | May 2004 → ? | liver and intrahepatic bile duct neoplasm, metastasis from malignant tumor of colon | Light Sciences LLC | Completed | No outcome recorded |
| Phase 2 | NCT00068068 | Oct 2003 → ? | colorectal neoplasm, liver and intrahepatic bile duct neoplasm, metastatic neoplasm | Light Sciences LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00440310 | Feb 2007 → May 2011 | metastasis from malignant tumor of colon | Light Sciences Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00355355 | Jul 2006 → Sep 2012 | hepatocellular carcinoma | Light Sciences Oncology | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02326454 Comparator | Nov 2014 → Mar 2017 | benign prostatic hyperplasia | Light Sciences Oncology | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Talaporfin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00068068 ↗ |
| Known as | LS11 | “The purpose of the study is to assess the survival of patients treated with Litx™ versus standard of care therapies in the treatment of unresectable hepatocellular carcinoma...” NCT00355355 ↗5“LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).” NCT00440310 ↗ “Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)” NCT00102115 ↗ “Talaporfin sodium (LS11)” NCT00068068 ↗ “Talaporfin Sodium (LS11)” NCT00122876 ↗ “Talaporfin sodium (LS11)” NCT00083785 ↗ |
| Known as | Talaporfin Sodium | “This is a phase 2 study to evaluate the safety and effectiveness of light-activated talaporfin sodium in patients with LUTS due to benign prostatic hyperplasia (BPH).” NCT00918034 ↗8“a photosensitizer medication called Talaporfin sodium” NCT01924273 ↗ “Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)” NCT00102115 ↗ “Talaporfin sodium (LS11)” NCT00068068 ↗ “Talaporfin sodium (LS11)” NCT00083785 ↗ |
| Modality | Other / unclassified | “an intravenously administered investigational photosensitizer” NCT01924273 ↗ |
| Route | Intravenous | “intravenous dose of LS11” NCT00122876 ↗ |